Sanofi-Aventis is a global healthcare company dedicated to improving health and well-being through the development and production of a wide range of pharmaceutical products and vaccines
With a strong focus on research and innovation, the company operates in various therapeutic areas, including diabetes, oncology, cardiovascular disease, central nervous system disorders, immunology, and rare diseases. Sanofi-Aventis also emphasizes the importance of vaccines in disease prevention and offers a portfolio that addresses public health needs. The company strives to enhance patients' quality of life by providing effective treatments and advancing healthcare solutions worldwide.
Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch
Apogee's APG990 Phase 1 data show a 60-day half-life and strong tolerability, supporting long-interval dosing. A 2025 trial will compare APG279 to Dupixent.
Novavax reported Q4 sales of $88.31 million, beating estimates despite a decline. The company shifts focus to partnerships and expects up to $350 million in 2025 revenue.
Regeneron is trading at historically low valuations as its Dupixent blockbuster drug could get a 30% increase in TAM if the FDA approves its use in COPD.
Teva and Sanofi's duvakitug showed promising results in a Phase 2b study for ulcerative colitis and Crohn's disease, with plans for a Phase 3 trial in 2025.
Sanofi and J&J halted a phase 3 E. coli vaccine trial due to insufficient efficacy. Sanofi's Q4 2024 IFRS EPS dropped by €0.15 following a $250M charge.
Sanofi has purchased 2.3% of its shares from L'Oréal SA as part of its share repurchase program. The €3 billion deal involves acquiring 29.6 million shares at €101.50 each, with cancellation expected by April 29, 2025.
The Centers for Disease Control and Prevention abruptly ordered its staff to cease all collaboration with the World Health Organization on Monday, marking a dramatic acceleration of President Donald Trump's executive order to withdraw from the global health body.
